Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia
This article was originally published in The Pink Sheet Daily
Executive Summary
Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.